Traphagen Investment Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Traphagen Investment Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-98,840	Closed	-$8.22M	–	169
2023 Q2	$8.22M	Buy	98,840 +1,684	+2%	+$141K	1.07%	18
2023 Q1	$7.41M	Buy	97,156 +1,012	+1%	+$84K	1.09%	16
2022 Q4	$7.98M	Buy	96,144 +784	+0.8%	+$63.5K	1.25%	16
2022 Q3	$7.56M	Sell	95,360 -67	-0.1%	-$5.65K	1.39%	17
2022 Q2	$7.09M	Buy	95,427 +7,444	+8%	+$559K	1.29%	18
2022 Q1	$7.91M	Sell	87,983 -19,253	-18%	-$1.78M	1.28%	17
2021 Q4	$6.32M	Sell	107,236 -28,975	-21%	-$3.49M	1.04%	16
2021 Q3	$8.3M	Buy	136,211 +115,739	+565%	+$14.9M	1.49%	14
2021 Q2	$1.37M	Buy	20,472 +8,179	+67%	+$1.08M	0.23%	36
2021 Q1	$832K	Buy	+12,293	New	+$1.84M	0.15%	57

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Traphagen Investment Advisors's XBI Position: Q3 2023 in Review

Traphagen Investment Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2023, closing a stake of 98,840 shares — an estimated $8.22M sold.

Traphagen Investment Advisors first reported a position in XBI in Q1 2021 and held it in 10 quarters. The position peaked at $8.3M in Q3 2021. 677 funds tracked by Wall St. Rank hold XBI as of Q3 2023.

Traphagen Investment Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2023 after selling out during the quarter.
Traphagen Investment Advisors sold 98,840 State Street SPDR S&P Biotech ETF shares in Q3 2023, an estimated $8.22M.
Traphagen Investment Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and held it in 10 quarters.
Traphagen Investment Advisors's State Street SPDR S&P Biotech ETF position peaked at $8.3M in Q3 2021.
677 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2023.

Based on Traphagen Investment Advisors's 13F filing for Q3 2023, filed 17 Jun 2024.